gefitinib has been researched along with semaxinib in 8 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (semaxinib) | Trials (semaxinib) | Recent Studies (post-2010) (semaxinib) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 480 | 31 | 218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Arlot, Y; Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bocci, G; Cosconati, S; D'Ocon, P; Da Settimo, F; Dalla Via, L; Fioravanti, A; Fornaciari, G; García-Argáez, AN; Gia, O; La Motta, C; Marini, AM; Novellino, E; Orlandi, P; Salerno, S; Sartini, S; Simorini, F; Taliani, S | 1 |
| Kuwano, M; Ono, M | 1 |
| Garber, K | 1 |
| Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A | 1 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
1 review(s) available for gefitinib and semaxinib
| Article | Year |
|---|---|
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
7 other study(ies) available for gefitinib and semaxinib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Topics: Amides; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors | 2003 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |